| Evotec (UK) Ltd | ||
 | ||
| ||
| ||
 |
||
|
||
| ||
| ||
| ||
|
||
| contact | ||
| 111 Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UNITED KINGDOM Map | ||
| Tel:01235 838875 | ||
| Fax:01235 863139 | ||
| Email: | ||
| Web:http://www.evotec.com | ||
|
||
| main contacts | ||
| Mr Shane Pereira (Marketing Communications Manager) | ||
| ||
| ||
| ||
YOUR FULLY INTEGRATED DRUG DISCOVERY & DEVELOPMENT SERVICE PROVIDER Critical Success Factors 1. Fully integrated R&D solutions 2. Critical mass in science skills and facilities 3. Outstanding customer network & references 4. Track record for delivery includes more than ten pre-clinical candidates and four drugs approved for clinical testing
| ||
| Full Profile: | ||
| Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through contract research partnerships, the Company is providing highest quality research results to its partners in the pharmaceutical and biotechnology industries.
In proprietary projects, Evotec specialises in finding new treatments for diseases of the central nervous system (CNS). Evotec has three Phase I clinical programmes: EVT 201, a GABA-A modulator for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease, Parkinson's disease and neuropathic pain and EVT 301, a selective and reversible inhibitor of MAO-B for the treatment of Alzheimer's disease. In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing. In 2005, based on preliminary numbers Evotec has generated sales of EUR 79 million with 600 people located in Hamburg, Germany and near Oxford and in Glasgow, UK. |
||
| ||
| ||
| ||
|